At REMD we believe that innovative protein therapeutics and strong science can change the practice of medicine. Through innovation and collaborations, we strive to create new treatments that are effective, safe and affordable for patients suffering from metabolic diseases, cancer and other serious illnesses.
REMD Biotherapeutics Inc is a privately held clinical-stage biopharmaceutical company with R&D operations located in the US and China. The company was founded in Camarillo, CA in 2011 by two seasoned former Amgen research scientists and has R&D operations in Camarillo and Beijing.
Our most advanced program is Volagidemab (REMD-477), a fully human antibody antagonizing human Glucagon Receptor. We have completed Phase 2 clinical studies with Volagidemab in Type 1 and Type 2 Diabetes in the US and are planning a Phase 3 study in Type 1 Diabetes. In addition, Volagidemab is in Phase 2 clinical development treating PI3K inhibitor-induced iatrogenic hyperglycemia in cancer patients. Moreover, the antibody has demonstrated beneficial therapeutic effects in multiple heart failure preclinical models by modulating metabolism of the heart.
Our robust pipeline is maintained and enriched with our extensive expertise in developing therapeutic antibodies to G Protein Coupled Receptors (GPCRs) and our innovative approaches in generating bispecific antibodies including our SynermAb and Antigen Targeted Attenuated Cytokine (ATAC) Platforms.